Aurinia Pharmaceuticals Inc. (FRA:IKAP)
Germany · Delayed Price · Currency is EUR 13.88
-0.20 (-1.42%)
Last updated: Nov 27, 2025, 8:02 AM CET
Aurinia Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 265.81 | 235.13 | 175.51 | 134.03 | 45.61 | 50.12 | Upgrade | |
Revenue Growth (YoY) | 20.62% | 33.97% | 30.95% | 193.89% | -9.01% | 15660.38% | Upgrade |
Cost of Revenue | 52.73 | 49.03 | 63.79 | 50.65 | 52.23 | 50.33 | Upgrade |
Gross Profit | 213.08 | 186.1 | 111.72 | 83.38 | -6.63 | -0.21 | Upgrade |
Selling, General & Admin | 109.57 | 172.03 | 195.04 | 196.37 | 173.54 | 97.27 | Upgrade |
Other Operating Expenses | 16 | 1.55 | 2.48 | -1.52 | 0.57 | 6.81 | Upgrade |
Operating Expenses | 131.97 | 173.58 | 197.52 | 194.85 | 174.11 | 104.08 | Upgrade |
Operating Income | 81.1 | 12.52 | -85.79 | -111.47 | -180.74 | -104.29 | Upgrade |
Interest Expense | -4.43 | -4.84 | -2.78 | - | - | - | Upgrade |
Interest & Investment Income | 14.06 | 16.97 | 17 | 5.12 | 0.53 | 1.52 | Upgrade |
Currency Exchange Gain (Loss) | 5.9 | 5.9 | -5.9 | - | - | - | Upgrade |
EBT Excluding Unusual Items | 96.64 | 30.55 | -77.47 | -106.35 | -180.21 | -102.77 | Upgrade |
Merger & Restructuring Charges | -17 | -23.11 | - | - | - | - | Upgrade |
Pretax Income | 79.64 | 7.45 | -77.47 | -106.35 | -180.21 | -102.77 | Upgrade |
Income Tax Expense | 1.8 | 1.7 | 0.55 | 1.83 | 0.76 | -0.09 | Upgrade |
Net Income | 77.84 | 5.75 | -78.02 | -108.18 | -180.97 | -102.68 | Upgrade |
Net Income to Common | 77.84 | 5.75 | -78.02 | -108.18 | -180.97 | -102.68 | Upgrade |
Shares Outstanding (Basic) | 137 | 143 | 143 | 142 | 129 | 118 | Upgrade |
Shares Outstanding (Diluted) | 142 | 146 | 143 | 142 | 129 | 118 | Upgrade |
Shares Change (YoY) | -1.24% | 2.07% | 0.93% | 9.70% | 9.20% | 27.36% | Upgrade |
EPS (Basic) | 0.57 | 0.04 | -0.54 | -0.76 | -1.40 | -0.87 | Upgrade |
EPS (Diluted) | 0.55 | 0.04 | -0.54 | -0.76 | -1.40 | -0.87 | Upgrade |
Free Cash Flow | 119.64 | 44.11 | -34.18 | -79.82 | -158 | -75.53 | Upgrade |
Free Cash Flow Per Share | 0.84 | 0.30 | -0.24 | -0.56 | -1.22 | -0.64 | Upgrade |
Gross Margin | 80.16% | 79.15% | 63.66% | 62.21% | -14.53% | -0.42% | Upgrade |
Operating Margin | 30.51% | 5.32% | -48.88% | -83.17% | -396.31% | -208.09% | Upgrade |
Profit Margin | 29.28% | 2.45% | -44.45% | -80.71% | -396.81% | -204.88% | Upgrade |
Free Cash Flow Margin | 45.01% | 18.76% | -19.47% | -59.55% | -346.44% | -150.70% | Upgrade |
EBITDA | 100.55 | 31.96 | -74.14 | -108.76 | -177.97 | -102.92 | Upgrade |
EBITDA Margin | 37.83% | 13.59% | -42.24% | -81.15% | - | -205.35% | Upgrade |
D&A For EBITDA | 19.45 | 19.45 | 11.65 | 2.71 | 2.76 | 1.37 | Upgrade |
EBIT | 81.1 | 12.52 | -85.79 | -111.47 | -180.74 | -104.29 | Upgrade |
EBIT Margin | 30.51% | 5.32% | -48.88% | -83.17% | - | -208.09% | Upgrade |
Effective Tax Rate | 2.26% | 22.77% | - | - | - | - | Upgrade |
Revenue as Reported | 265.81 | 235.13 | 175.51 | 134.03 | 45.61 | 50.12 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.